{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:40:24Z","timestamp":1764240024259},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.dld.2016.10.010","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T03:17:51Z","timestamp":1477451871000},"page":"301-307","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension"],"prefix":"10.1016","volume":"49","author":[{"given":"Ludivine","family":"Legros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Chabanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Camus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Fournet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Houssel-Debry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Latournerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Jezequel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Rayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Boudjema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Guyader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Bardou-Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.10.010_bib0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/lt.23485","article-title":"Portopulmonary hypertension: an update","volume":"18","author":"Safdar","year":"2012","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.dld.2016.10.010_bib0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.10.010_bib0025","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1600-6143.2008.02384.x","article-title":"Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups","volume":"8","author":"Swanson","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/lt.20459","article-title":"Hemodynamics and survival of patients with portopulmonary hypertension","volume":"11","author":"Kawut","year":"2005","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Galie","year":"2009","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.dld.2016.10.010_bib0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00408-013-9501-5","article-title":"Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center\u2019s experience","volume":"191","author":"Awdish","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.dld.2016.10.010_bib0045","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/thx.2005.040618","article-title":"Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol","volume":"60","author":"Sitbon","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.dld.2016.10.010_bib0050","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2016.10.010_bib0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2016.10.010_bib0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jlts.2000.6356","article-title":"Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation","volume":"6","author":"Krowka","year":"2000","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0065","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the study of liver diseases and the American Society of Transplantation","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.10.010_bib0070","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","article-title":"Management of pulmonary arterial hypertension","volume":"65","author":"McLaughlin","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.dld.2016.10.010_bib0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.10.010_bib0080","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.dld.2016.10.010_bib0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/lt.21310","article-title":"Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension","volume":"14","author":"Austin","year":"2008","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1665-2681(19)31798-3","article-title":"The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation","volume":"8","author":"Cadden","year":"2009","journal-title":"Annals of Hepatology"},{"issue":"Suppl. 3","key":"10.1016\/j.dld.2016.10.010_bib0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2362.2006.01687.x","article-title":"Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C","volume":"36","author":"Grander","year":"2006","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.dld.2016.10.010_bib0100","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.20153","article-title":"Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation","volume":"10","author":"Makisalo","year":"2004","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/lt.21533","article-title":"Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension","volume":"15","author":"Gough","year":"2009","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.21479","article-title":"Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation","volume":"15","author":"Hemnes","year":"2009","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0115","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1183\/09031936.00032407","article-title":"Experience with inhaled iloprost and bosentan in portopulmonary hypertension","volume":"30","author":"Hoeper","year":"2007","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.dld.2016.10.010_bib0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00117511","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","author":"Savale","year":"2013","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.dld.2016.10.010_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.10-0574","article-title":"Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension","volume":"139","author":"Cartin-Ceba","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.dld.2016.10.010_bib0130","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors","volume":"178","author":"Le Pavec","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.dld.2016.10.010_bib0135","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/lt.21174","article-title":"Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol","volume":"13","author":"Fix","year":"2007","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2016.10.010_bib0140","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1600-6143.2006.01701.x","article-title":"The impact of treatment of portopulmonary hypertension on survival following liver transplantation","volume":"7","author":"Ashfaq","year":"2007","journal-title":"American Journal of Transplantation"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T01:29:04Z","timestamp":1568510944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816307769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1590865816307769"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.10.010","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}